Zobrazeno 1 - 10
of 10
pro vyhledávání: '"David Sandak"'
Autor:
Andrew L Hong, Yuen-Yi Tseng, Jeremiah A Wala, Won-Jun Kim, Bryan D Kynnap, Mihir B Doshi, Guillaume Kugener, Gabriel J Sandoval, Thomas P Howard, Ji Li, Xiaoping Yang, Michelle Tillgren, Mahmhoud Ghandi, Abeer Sayeed, Rebecca Deasy, Abigail Ward, Brian McSteen, Katherine M Labella, Paula Keskula, Adam Tracy, Cora Connor, Catherine M Clinton, Alanna J Church, Brian D Crompton, Katherine A Janeway, Barbara Van Hare, David Sandak, Ole Gjoerup, Pratiti Bandopadhayay, Paul A Clemons, Stuart L Schreiber, David E Root, Prafulla C Gokhale, Susan N Chi, Elizabeth A Mullen, Charles WM Roberts, Cigall Kadoch, Rameen Beroukhim, Keith L Ligon, Jesse S Boehm, William C Hahn
Publikováno v:
eLife, Vol 8 (2019)
Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African descent with sickle cell trait. We have developed faithful patient-derived RMC models and using whole-genome sequencing, we identified loss-of-function intronic
Externí odkaz:
https://doaj.org/article/ea9c3a1d96864bb8bbdbc626e575f019
Publikováno v:
Foot & Ankle Orthopaedics, Vol 7 (2022)
Externí odkaz:
https://doaj.org/article/f0793acd024144d78a15fe6e911e2f8b
Publikováno v:
Foot & Ankle Orthopaedics. 7:247301142211129
Autor:
Kathy Oliver, Kay Verble, Amanda Bates, Minesh P. Mehta, Marta Penas-Prado, Patrick Y. Wen, Brian M. Alexander, Martin J. van den Bent, Michael A. Vogelbaum, Shawn L. Hervey-Jumper, David A. Reardon, Bret E Friday, David Sandak, Thomas Halkin, Ugonma Chukwueke, Al Musella, Michael Weller, Jose Pablo Leone, Eudocia Q. Lee, David R. Macdonald, John de Groot, David Arons, Nicole Willmarth, Terri Armstrong, Nan Lin, Sarah C. Gaffey, Lisa Doherty, Evanthia Galanis, Maryam Fouladi, Solmaz Sahebjam, Susan M. Chang
Publikováno v:
Neuro-Oncology, 21(9), 1100-1117. Oxford University Press
Neuro-oncology, vol 21, iss 9
Neuro Oncol
Neuro-oncology, vol 21, iss 9
Neuro Oncol
Many factors contribute to the poor survival of malignant brain tumor patients, some of which are not easily remedied. However, one contributor to the lack of progress that may be modifiable is poor clinical trial accrual. Surveys of brain tumor pati
Autor:
Abeer Sayeed, Xiaoping Yang, Elizabeth Mullen, Gabriel J. Sandoval, Pratiti Bandopadhayay, Michelle Tillgren, Andrew L. Hong, William C. Hahn, Abigail Ward, Katherine Labella, Brian McSteen, Rameen Beroukhim, Adam Tracy, Mihir B. Doshi, Charles W. M. Roberts, Prafulla C. Gokhale, Won Jun Kim, Jesse S. Boehm, Mahmhoud Ghandi, Stuart L. Schreiber, David E. Root, Ji Li, Susan N. Chi, Jeremiah Wala, Ole Gjoerup, Cora Connor, Paul A. Clemons, Katherine A. Janeway, Thomas P. Howard, Alanna J. Church, Bryan D. Kynnap, David Sandak, Cigall Kadoch, Keith L. Ligon, Brian D. Crompton, Paula Keskula, Yuen-Yi Tseng, Rebecca Deasy, Guillaume Kugener, Barbara Van Hare, Catherine Clinton
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b44f99bc17d54121519cb0d6df6c5b3
https://doi.org/10.7554/elife.44161.051
https://doi.org/10.7554/elife.44161.051
Autor:
Adam J. Bass, Grace Johnson, Priya Chatterji, Yuen-Yi Tseng, Rebecca Deasy, Mushriq AI-Jazrawe, Francisca Vasquez, Jesse S. Boehm, Paula Keskula, Barbara Van Hare, Keith L. Ligon, David Sandak, Andrew L. Hong
Publikováno v:
Cancer Research. 80:3453-3453
Precision cancer medicine is based on the ability to predict the dependencies of a given tumor from its molecular makeup. Despite successes in multiple common cancers, such prediction remains challenging for the majority of rare and understudied tumo
Autor:
Adam J. Bass, Jesse S. Boehm, Andrew L. Hong, David Sandak, Paula Keskula, Barbara Van Hare, Keith L. Ligon, Priya Chatterji, Francisca Vazquez, Yuen-Yi Tseng, Rebecca Deasy
Publikováno v:
Cancer Research. 80:PR09-PR09
Precision cancer medicine is based on the ability to predict the dependencies of a given tumor from its molecular makeup. Despite successes in multiple common cancers, such prediction remains challenging for the majority of rare and understudied tumo
Autor:
Shakti Ramkissoon, Brian M. Alexander, Azra H. Ligon, David Sandak, David S. Knoff, Patrick Y. Wen, Rameen Beroukhim, Shyam K. Tanguturi, Kristine Pelton, Neal I. Lindeman, Keith L. Ligon, Lorenzo Trippa, Giovanni Parmigiani
Publikováno v:
Neuro-oncology. 19(7)
Background Biomarkers can improve clinical trial efficiency, but designing and interpreting biomarker-driven trials require knowledge of relationships among biomarkers, clinical covariates, and endpoints. We investigated these relationships across ge
Autor:
Martin Bendszus, Caroline Chung, W. K. Alfred Yung, Daniel P. Barboriak, Michael V. Knopp, Elizabeth R. Gerstner, Dewen Yang, Evanthia Galanis, Chas Haynes, Bradley J. Erickson, David Arons, Timothy F. Cloughesy, Andrew Whitney, Mark R. Gilbert, Jayashree Kalpathy-Cramer, Paula M. Jacobs, Al Musella, Whitney B. Pope, Gregory V. Goldmacher, Patrick Y. Wen, Sarah J. Nelson, Brian M. Alexander, Marion Smits, Soonme Cha, Jerrold L. Boxerman, David Sandak, Michael A. Vogelbaum, Wolfgang Wick, Benjamin M. Ellingson, Lalitha K. Shankar, Susan M. Chang, Max Wallace, Martin J. van den Bent, Michael Weller, Ann E Kingston
Publikováno v:
Neuro-Oncology, 17(9), 1188-1198. Oxford University Press
A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and
Autor:
Yuen-Yi Tseng, Andrew Hong, Paula Keskula, Shubhroz Gill, Jaime Cheah, Grigoriy Kryukov, Aviad Tsherniak, Francisca Vazquez, Glenn Cowley, Sahar Alkhairy, Coyin Oh, Anson Peng, Rebecca Deasy, Abeer Sayeed, Peter Ronning, Samuel Ng, Steven Corsello, Corrie Painter, David Sandak, Levi Garraway, Mark Rubin, Calvin Kuo, Sidharth Puram, David Weinstock, Adam Bass, Nikhil Wagle, Keith Ligon, Katherine Janeway, David Root, Stuart Schreiber, Paul Clemons, Aly Shamji, William Hahn, Todd Golub, Jesse Boehm
Publikováno v:
Cancer Research. 77:1953-1953
Ongoing pre-clinical efforts aim to deploy genome-scale CRISPR/Cas9 technology and large collections of small molecules to catalog maps of cancer vulnerabilities at scale. However, such efforts in pediatric and rare cancers have lagged behind compara